Previous Close | 88.35 |
Open | 88.99 |
Bid | 78.53 x 1300 |
Ask | 88.85 x 800 |
Day's Range | 88.67 - 89.71 |
52 Week Range | 69.44 - 91.08 |
Volume | |
Avg. Volume | 877,287 |
Market Cap | 43.963B |
Beta (5Y Monthly) | 0.68 |
PE Ratio (TTM) | 42.24 |
EPS (TTM) | 2.11 |
Earnings Date | Aug 20, 2024 |
Forward Dividend & Yield | 0.27 (0.30%) |
Ex-Dividend Date | May 14, 2024 |
1y Target Est | 94.60 |
Shareholders approved all agenda items and proposals of the Board of DirectorsRobert K. Warner, M.B.A. and Arshad M. Khanani, M.D., M.A., FASRS elected as members of the Board of DirectorsBaruch D. Kuppermann, M.D., Ph.D. and Frank G. Holz, M.D., Ph.D. appointed as members of the Scientific Advisory BoardOculis established a CHF 50 million flexible loan facility with funds and accounts managed by BlackRock ZUG, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: O
Here is how Alcon (ALC) and CalciMedica Inc. (CALC) have performed compared to their sector so far this year.
Investors need to pay close attention to Alcon (ALC) stock based on the movements in the options market lately.